The effects of systemic anti-infective concomitant medications on progression of neurological diseases

The effects of systemic anti-infective concomitant medications on progression of neurological diseases

Various evidence suggests neurological conditions may be induced or exacerbated by microbial infections. Furthermore, it has been shown that anti-infective medications may have neuroprotective properties. A retrospective cohort study was chosen for this research as this will enable us to examine many type of diseases, and many groups of medications, without the need to expose new patients for a new investigation by using existing data. The availability of clinical data from various randomized studies makes such data an attractive source for systematic research on many diseases and many groups of anti-infective medications. We will examine the effect of anti-infective agents on progression

[{ "PostingID": 4086, "Title": "NOVARTIS-CENA713D1301", "Description": "A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)" },{ "PostingID": 4089, "Title": "NOVARTIS-CFTY720D2309", "Description": "24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase" },{ "PostingID": 4180, "Title": "NOVARTIS-CENA713B2311", "Description": "A 24-week Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Tolerability, and Safety of 3-12 mg/day of Rivastigmine Capsules in Patients with Parkinson’s Disease Dementia" },{ "PostingID": 4594, "Title": "NOVARTIS-CFTY720D2306", "Description": "A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis" },{ "PostingID": 20296, "Title": "NOVARTIS-CBAF312A2201", "Description": "A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis" }]